HPV Archives
Trial combines novel therapies for head and neck cancer
Apr. 27, 2023—Vanderbilt is launching a clinical trial that pairs an experimental vaccine with an established immunotherapy for recurrent, human papilloma virus (HPV)-related oropharyngeal cancer of the head and neck.
Study seeks to refine head and neck cancer treatment options
Jan. 13, 2022— by Bill Snyder Researchers at Case Western Reserve University and Vanderbilt University Medical Center are pioneering the use of computer-aided image analysis to improve the prognostication and treatment of head and neck cancer. Each year in the United States, approximately 16,000 patients are diagnosed with a form of head-and-neck cancer called oropharyngeal squamous cell...
New robot enhances accuracy of head, neck cancer surgeries
Oct. 21, 2021—by Emily Stembridge Vanderbilt Otolaryngology-Head and Neck Surgery has acquired an SP (single port) surgical robot that will help provide more targeted and accurate transoral robotic surgery (TORS) for patients with head and neck cancer. The new robot features a single port with a flexible camera and three different surgical instruments, as well as an...
Vanderbilt-Ingram Cancer Center calls for action to get cancer-preventing HPV vaccination back on track
May. 27, 2021—A significant reduction in annual well visits and immunizations during the COVID-19 pandemic has led to a vaccination gap among U.S. children and adolescents, especially with the human papillomavirus (HPV) vaccine for cancer prevention.
Vanderbilt-Ingram Cancer Center patient first for new cell engineering platform
Feb. 5, 2020—Rhea Dodd is the first patient treated with an experimental cancer vaccine derived from a completely new cell engineering platform.
Symposium explores prevention of HPV-associated cancers
Mar. 7, 2019—Physicians and researchers from across the country came to the Vanderbilt Symposium on HPV Infections and Associated Cancers on March 1 to discuss screening and prevention strategies for the human papillomavirus (HPV).
Awareness, education goal of new HPV initiative
Mar. 8, 2018—Vanderbilt is at the epicenter of a human papillomavirus (HPV)-associated cancer epidemic, according to Ronald Alvarez, MD, chair of the Department of Obstetrics and Gynecology at Vanderbilt.
Conference to focus on link between viruses and cancer
Jul. 12, 2017—The association between tobacco use and cancer is well known. But there are other risk factors for cancer that are less recognized, including the link between cancer and certain viruses.
Researchers seek best ways to increase HPV vaccination rates
May. 11, 2017—Tennessee has one of the lowest human papillomavirus (HPV) vaccination rates in the nation, and investigators at Vanderbilt University Medical Center (VUMC) are hoping to change this by improving the way medical providers present these vaccines to patients and by improving patient and patient family education.
National Cancer Institute’s Lowy details HPV virus research efforts
Feb. 2, 2017—Douglas Lowy, M.D., acting director of the National Cancer Institute (NCI), warned that worldwide death rates from cervical cancer are expected to increase in low- and middle-income countries during the next 15 years unless steps are taken to prevent the cancer from occurring. Almost all cases of cervical cancer are linked to a viral infection.
Vanderbilt-Ingram Cancer Center supports national HPV vaccination efforts
Jan. 17, 2017—Nearly 39,000 new cancers associated with the human papillomavirus (HPV) will be diagnosed in the United States this year. Although HPV vaccines can prevent the majority of these cancers, vaccination rates remain low across the country.
VICC joins other major cancer centers in HPV vaccine campaign
Feb. 4, 2016—In response to low national vaccination rates for the human papillomavirus (HPV), Vanderbilt-Ingram Cancer Center (VICC) has joined 68 of the nation’s other NCI-designated cancer centers in recommending increased HPV vaccination for the prevention of cancer.
